TP53 and cancer: Our observation is in line with the study by Sur and colleagues that cancer cell lines with or without p53 displayed only minor difference in the sensitivity of the Plk1 inhibitor BI 2536 [140], arguing against a direct role of defective p53 in the response to Plk1 inhibition.